Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$39.73M+11.0%-$37.8M-0.8%-$36.79M-6.7%-$42.08M-46.1%-$44.64M-67.2%
$351K-29.9%$368K-34.6%$415K-25.6%$515K-2.8%$501K+3.9%
$3.17M+46.7%$2.7M+95.5%$2.7M-20.9%$2.52M+96.1%$2.16M-5.1%
-$41.6M+7.4%-$33.53M+9.5%-$43.32M-57.6%-$31.95M-32.2%-$44.92M-76.0%
$2K-98.0%$4K-99.6%$0-100%
-$50.2M-1,000%$22.56M$29.17M+143%$5.58M+105%
$6.18M$6.18M$6.18M$6.18M
-$101K+75.6%$140.74M$1.49M-$649K-$414K-100%
-$91.9M-131%$89.93M-$19.28M-$3.43M-$39.75M-121%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Kyverna Therapeutics, Inc. generate?
Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
What is Kyverna Therapeutics, Inc.'s free cash flow?
After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.